Trial Profile
A multicenter, retrospective clinical study to evaluate the Vaccine-related uveitis after the BNT162b2 mRNA vaccination for SARS-CoV-2 infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications SARS-CoV-2 acute respiratory disease; Uveitis
- Focus Adverse reactions
- 03 Jan 2022 New trial record
- 01 Dec 2021 Results published in the Retina